Prognostic Value of Performance Scores in Patients Undergoing Surgery for Upper Tract Urothelial Carcinoma

Prognostic Value of Eastern Cooperative Oncology Group Performance Status and American Society of Anesthesiologists Score in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06305130

Enrollment

2515

Registered

2024-03-12

Start date

1988-01-01

Completion date

2023-12-31

Last updated

2024-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Transitional Cell (RENI)

Brief summary

Aim: to comprehensively evaluate the prognostic value of preoperative ECOG-PS scores and ASA scores in patients undergoing radical nephroureterectomy (RNU) for upper tract urothelial carcinoma. Methods: multicentered cohort study

Detailed description

Background: The Eastern Cooperative Oncology Group (ECOG) performance status (PS) score and the American Society of Anesthesiologists (ASA) score are essential tools for the assessment of patients with various malignancies. However, doubts have arisen regarding their prognostic utility due to conflicting findings in limited studies. This study aims to comprehensively evaluate the prognostic value of preoperative ECOG-PS scores and ASA scores in patients undergoing radical nephroureterectomy (RNU) for upper tract urothelial carcinoma. Materials and Methods: This multicentered cohort study enrolled patients who underwent RNU with curative intentat sixteen institutes in Taiwan from 1988 to 2023. Univariable and multivariable regression analyses were used to determine the impact of ECOG-PS scores and ASA scores on survival outcomes and postoperative complications. Patients were categorized based on ECOG-PS scores (0-1 vs. 2-4) and ASA scores (1-2 vs.3-4) according to prior literature.

Interventions

OTHERNo intervention

No intervention

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* All patients received UTUC surgery and follow-up in sixteen institutions across Taiwan

Exclusion criteria

* Treatment not aimed at curative intent * Incomplete data

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	1988 to 2023	in days
Cancer-specific survival	1988 to 2023	in days
Disease-free survival	1988 to 2023	in days
Bladder recurrence-free survival	1988 to 2023	in days

Secondary

Measure	Time frame	Description
Number of patients with major postoperative complication	1988 to 2023	Clavien-Dindo classification grade higher or equal to III
Number of patients with postoperative renal failure	1988 to 2023	Those who requiring renal replacement therapy permanently

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026